These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 22814222

  • 1. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
    Fauvel M, Farrugia C, Tsapis N, Gueutin C, Cabaret O, Bories C, Bretagne S, Barratt G.
    Int J Pharm; 2012 Oct 15; 436(1-2):106-10. PubMed ID: 22814222
    [Abstract] [Full Text] [Related]

  • 2. Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
    Kamalaporn H, Leung K, Nagel M, Kittanakom S, Calvieri B, Reithmeier RA, Coates AL.
    Pediatr Pulmonol; 2014 Jun 15; 49(6):574-80. PubMed ID: 23843366
    [Abstract] [Full Text] [Related]

  • 3. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR.
    Transpl Infect Dis; 2007 Jun 15; 9(2):121-5. PubMed ID: 17461997
    [Abstract] [Full Text] [Related]

  • 4. A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations.
    Menotti J, Alanio A, Sturny-Leclère A, Vitry S, Sauvage F, Barratt G, Bretagne S.
    Toxicol Appl Pharmacol; 2017 Nov 01; 334():18-23. PubMed ID: 28865757
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT, Gavaldà J, López P, Gomis X, Ramírez JL, Rodríguez D, Len O, Jordano Q, Ruiz I, Rosal M, Almirante B, Pahissa A.
    J Antimicrob Chemother; 2003 Dec 01; 52(6):1032-4. PubMed ID: 14613950
    [Abstract] [Full Text] [Related]

  • 6. Disposition of aerosolized liposomal amphotericin B.
    Lambros MP, Bourne DW, Abbas SA, Johnson DL.
    J Pharm Sci; 1997 Sep 01; 86(9):1066-9. PubMed ID: 9294824
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
    Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG.
    Antimicrob Agents Chemother; 2006 May 01; 50(5):1852-4. PubMed ID: 16641459
    [Abstract] [Full Text] [Related]

  • 9. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial.
    Slobbe L, Boersma E, Rijnders BJ.
    Pulm Pharmacol Ther; 2008 Dec 01; 21(6):855-9. PubMed ID: 18951992
    [Abstract] [Full Text] [Related]

  • 10. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ, Vulto AG, Van Etten EW.
    J Pharm Pharmacol; 2000 Jun 01; 52(6):619-27. PubMed ID: 10875537
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
    Usman F, Nopparat J, Javed I, Srichana T.
    Drug Deliv Transl Res; 2020 Feb 01; 10(1):59-69. PubMed ID: 31368043
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
    Alsaadi M, Italia JL, Mullen AB, Ravi Kumar MN, Candlish AA, Williams RA, Shaw CD, Al Gawhari F, Coombs GH, Wiese M, Thomson AH, Puig-Sellart M, Wallace J, Sharp A, Wheeler L, Warn P, Carter KC.
    J Control Release; 2012 Jun 28; 160(3):685-91. PubMed ID: 22516093
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bioactivity, Safety, and Efficacy of Amphotericin B Nanomicellar Aerosols Using Sodium Deoxycholate Sulfate as the Lipid Carrier.
    Usman F, Khalil R, Ul-Haq Z, Nakpheng T, Srichana T.
    AAPS PharmSciTech; 2018 Jul 28; 19(5):2077-2086. PubMed ID: 29691753
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
    Gavaldà J, Martín MT, López P, Gomis X, Ramírez JL, Rodríguez D, Len O, Puigfel Y, Ruíz I, Pahissa A.
    Antimicrob Agents Chemother; 2005 Jul 28; 49(7):3028-30. PubMed ID: 15980392
    [Abstract] [Full Text] [Related]

  • 20. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
    Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, Calvitti M, Pitzurra L, Romani L.
    J Antimicrob Chemother; 2005 Feb 28; 55(2):214-22. PubMed ID: 15649994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.